Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

  • STATUS
    Recruiting
  • participants needed
    84
  • sponsor
    Ascend Biopharmaceuticals Ltd
Updated on 2 February 2023
platelet count
carcinoma
neutrophil count
punch biopsy
infertility
vismodegib
asn-002
hedgehog pathway inhibitor

Summary

The primary objectives are to:

  1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s;
  2. Evaluate the efficacy of intralesional ASN-002 in target tumours when administered in combination with oral vismodegib in patients with BCCs.

The secondary objective is to:

  1. Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs.

The exploratory objective is to:

  1. Evaluate immunological biomarkers during the course of treatment.

Description

Methodology

This study will evaluate ASN-002 (in the dose range 0.5 to 1.5x10(11) vp/mL) with the Hh inhibitor vismodegib (Erivedge®). The study will initially evaluate two Arms receiving 1.0 x 10(11) vp/injection, and following a safety review, may implement further arms in an adaptive study design.

Following screening and baseline biopsies for target and non-target tumours, eligible subjects will be enrolled in the study.

Cycle 1: Treatment with vismodegib (daily dose of 150 mg) for 4 weeks and ASN-002 for 3 weeks (i.e., three ASN-002 injections in total):

  • Day 1 to Day 14 - vismodegib alone
  • Day 15 - vismodegib and ASN-002
  • Day 16 to Day 21 - vismodegib alone
  • Day 22 - vismodegib and ASN-002
  • Day 23 to Day 28 - vismodegib alone
  • Day 29 - ASN-002 alone

Clinical response will be assessed at Week 17, following which, the investigator may where clinically indicated, initiate Cycle 2.

Cycle 2: Treatment with vismodegib (daily dose of 150 mg) for 4 weeks, and one further injection with ASN-002:

  • Day 1 to Day 7 - vismodegib alone
  • Day 8 - vismodegib and ASN-002
  • Day 9 to Day 28 - vismodegib alone

Surgical excision for all patients will occur between Week 25 and Week 33 at the investigators discretion, and dependent on when patient completed study treatment (1 or 2 treatment cycles). Up to 10 BCCs to be excised including 3 target tumours. Excisions can be conducted over 2 visits as per Investigator's discretion.

The Investigator may enrol eligible patients parallel into either Arm 1 or Arm 2, based on the number of tumours present. Up to 10 study BCC tumours (up to 3 target and up to 7 non-target) will be selected per patient.

Following review of at least Week 5 data for N=6 patients in Arm 1 and Arm 2, further Arms with varying doses of ASN-002 (in the dose range 0.5x10(11) vp or 1.5x10(11) vp) may be explored at the discretion of the Safety Review Committee (SRC). Vismodegib or ASN-002 may be evaluated as monotherapies to provide control groups to allow comparison of treatment Arms.

Safety and clinical assessments will be performed at Weeks 1, 3, 4, 5, 7, 17, 25 to 33.

Histological response will be evaluated in all study tumours via excision between Week 25 and Week 33 (as per investigator's discretion).

Six patients will be recruited to each Arm of the study, each Arm may be expanded to 12 patients at the discretion of the SRC.

Details
Condition Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Treatment ASN-002
Clinical Study IdentifierNCT04416516
SponsorAscend Biopharmaceuticals Ltd
Last Modified on2 February 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note